# Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

> **NCT00509431** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Erlotinib + Sirolimus

## Key facts

- **NCT ID:** NCT00509431
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-12
- **Final completion:** 2012-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509431, "Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00509431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*